CO2023010710A2 - Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d - Google Patents
Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12dInfo
- Publication number
- CO2023010710A2 CO2023010710A2 CONC2023/0010710A CO2023010710A CO2023010710A2 CO 2023010710 A2 CO2023010710 A2 CO 2023010710A2 CO 2023010710 A CO2023010710 A CO 2023010710A CO 2023010710 A2 CO2023010710 A2 CO 2023010710A2
- Authority
- CO
- Colombia
- Prior art keywords
- mutant kras
- pancreatic cancer
- compound
- quinazoline compound
- kras protein
- Prior art date
Links
- -1 Quinazoline compound Chemical class 0.000 title abstract 3
- 230000015556 catabolic process Effects 0.000 title abstract 2
- 238000006731 degradation reaction Methods 0.000 title abstract 2
- 101150105104 Kras gene Proteins 0.000 title 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 4
- 201000002528 pancreatic cancer Diseases 0.000 abstract 4
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 4
- 102100030708 GTPase KRas Human genes 0.000 abstract 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102200006539 rs121913529 Human genes 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
RESUMEN [Problema] Proporcionar un compuesto útil como ingrediente activo de una composición farmacéutica para tratar el cáncer de páncreas. [Medio de resolución] Los presentes inventores han estudiado un compuesto que es útil como ingrediente activo de una composición farmacéutica para tratar el cáncer de páncreas y han descubierto que un compuesto de quinazolina tiene una excelente acción inductora de degradación sobre una proteína KRAS mutante G12D y una actividad inhibidora de KRAS mutante G12D, y puede usarse como agente terapéutico para el cáncer de páncreas, con lo cual se completa la presente invención. El compuesto de quinazolina o una sal de este de la presente invención se puede usar como agente terapéutico para el cáncer de páncreas. [Dibujo seleccionado] Ninguno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021021656 | 2021-02-15 | ||
| PCT/JP2022/005582 WO2022173032A1 (ja) | 2021-02-15 | 2022-02-14 | Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023010710A2 true CO2023010710A2 (es) | 2023-09-18 |
Family
ID=82838828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0010710A CO2023010710A2 (es) | 2021-02-15 | 2023-08-16 | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240182483A1 (es) |
| EP (1) | EP4293024A1 (es) |
| JP (2) | JP7169729B1 (es) |
| KR (1) | KR20230145361A (es) |
| CN (1) | CN116848120A (es) |
| AR (1) | AR124870A1 (es) |
| AU (1) | AU2022221145A1 (es) |
| BR (1) | BR112023015067A2 (es) |
| CA (1) | CA3211051A1 (es) |
| CL (1) | CL2023002383A1 (es) |
| CO (1) | CO2023010710A2 (es) |
| CR (1) | CR20230404A (es) |
| DO (1) | DOP2023000161A (es) |
| EC (1) | ECSP23067156A (es) |
| IL (1) | IL305077A (es) |
| MX (1) | MX2023009521A (es) |
| PE (1) | PE20240235A1 (es) |
| TW (1) | TW202245751A (es) |
| WO (1) | WO2022173032A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023119677A1 (en) * | 2021-12-24 | 2023-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising a quinazoline compound |
| AR128761A1 (es) * | 2022-03-11 | 2024-06-12 | Astellas Pharma Inc | Compuesto heterocíclico para inducir la degradación de la proteína kras mutante en g12d |
| WO2024029613A1 (ja) * | 2022-08-05 | 2024-02-08 | アステラス製薬株式会社 | 変異ｋｒａｓタンパクの分解を誘導するための複素環化合物 |
| TW202413346A (zh) * | 2022-08-09 | 2024-04-01 | 日商安斯泰來製藥股份有限公司 | 用於誘導g12v突變kras蛋白之分解之雜環化合物 |
| TW202412790A (zh) * | 2022-08-09 | 2024-04-01 | 日商安斯泰來製藥股份有限公司 | 用於抑制及/或誘導分解kras蛋白之雜環化合物 |
| TW202412809A (zh) * | 2022-08-12 | 2024-04-01 | 日商安斯泰來製藥股份有限公司 | 包含標靶療法的抗癌組合 |
| WO2024033538A1 (en) * | 2022-08-12 | 2024-02-15 | Astellas Pharma Inc. | Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity |
| WO2024034123A1 (ja) * | 2022-08-12 | 2024-02-15 | アステラス製薬株式会社 | 複素環化合物を含む医薬組成物 |
| CN115873018B (zh) * | 2022-11-18 | 2024-03-15 | 中国药科大学 | 苯并嘧啶和苯并三嗪类造血祖细胞激酶1降解剂及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2802608A4 (en) * | 2012-01-12 | 2015-08-05 | Univ Yale | COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY E3 UBIQUITIN LIGASE |
| KR20210132233A (ko) | 2014-04-14 | 2021-11-03 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JOP20190186A1 (ar) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| JP2021521112A (ja) | 2018-04-04 | 2021-08-26 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | タンパク質分解の調節因子および関連する使用方法 |
| EP3823613A4 (en) | 2018-07-20 | 2022-05-11 | Dana Farber Cancer Institute, Inc. | DEGRADATION AGENTS TARGETING PROTEINS THROUGH KEAP1 |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2021051034A1 (en) | 2019-09-13 | 2021-03-18 | Biotheryx, Inc. | Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
-
2022
- 2022-02-14 AR ARP220100290A patent/AR124870A1/es unknown
- 2022-02-14 IL IL305077A patent/IL305077A/en unknown
- 2022-02-14 WO PCT/JP2022/005582 patent/WO2022173032A1/ja active Application Filing
- 2022-02-14 PE PE2023002366A patent/PE20240235A1/es unknown
- 2022-02-14 MX MX2023009521A patent/MX2023009521A/es unknown
- 2022-02-14 TW TW111105240A patent/TW202245751A/zh unknown
- 2022-02-14 EP EP22752854.4A patent/EP4293024A1/en active Pending
- 2022-02-14 CR CR20230404A patent/CR20230404A/es unknown
- 2022-02-14 JP JP2022542202A patent/JP7169729B1/ja active Active
- 2022-02-14 CN CN202280014815.8A patent/CN116848120A/zh active Pending
- 2022-02-14 AU AU2022221145A patent/AU2022221145A1/en active Pending
- 2022-02-14 US US18/268,001 patent/US20240182483A1/en active Pending
- 2022-02-14 KR KR1020237027669A patent/KR20230145361A/ko unknown
- 2022-02-14 BR BR112023015067A patent/BR112023015067A2/pt unknown
- 2022-02-14 CA CA3211051A patent/CA3211051A1/en active Pending
- 2022-10-27 JP JP2022172197A patent/JP2022191505A/ja active Pending
-
2023
- 2023-08-11 CL CL2023002383A patent/CL2023002383A1/es unknown
- 2023-08-15 DO DO2023000161A patent/DOP2023000161A/es unknown
- 2023-08-16 CO CONC2023/0010710A patent/CO2023010710A2/es unknown
- 2023-09-05 EC ECSENADI202367156A patent/ECSP23067156A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230145361A (ko) | 2023-10-17 |
| JP2022191505A (ja) | 2022-12-27 |
| CN116848120A (zh) | 2023-10-03 |
| AR124870A1 (es) | 2023-05-17 |
| PE20240235A1 (es) | 2024-02-16 |
| DOP2023000161A (es) | 2023-09-29 |
| JPWO2022173032A1 (es) | 2022-08-18 |
| TW202245751A (zh) | 2022-12-01 |
| MX2023009521A (es) | 2023-08-24 |
| JP7169729B1 (ja) | 2022-11-11 |
| ECSP23067156A (es) | 2023-10-31 |
| CA3211051A1 (en) | 2022-08-18 |
| IL305077A (en) | 2023-10-01 |
| BR112023015067A2 (pt) | 2023-10-03 |
| CR20230404A (es) | 2023-09-21 |
| AU2022221145A1 (en) | 2023-09-21 |
| EP4293024A1 (en) | 2023-12-20 |
| WO2022173032A1 (ja) | 2022-08-18 |
| CL2023002383A1 (es) | 2024-01-19 |
| US20240182483A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023010710A2 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
| CO2019008487A2 (es) | Compuesto de quinazolina | |
| CL2023000848A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| PE20211584A1 (es) | Compuestos antagonistas de pcsk9 | |
| DOP2019000294A (es) | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas | |
| CY1119488T1 (el) | Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου | |
| CL2019003892A1 (es) | Nuevos derivados de azaquinolina. | |
| EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
| CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
| ECSP067076A (es) | Derivados de pirimidina urea como inhibidores de la quinasa | |
| EA202191361A1 (ru) | Способы лечения муковисцидоза | |
| BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
| CO2019002246A2 (es) | Compuesto heterocíclico nitrogenado bicíclico | |
| CL2023000524A1 (es) | Compuestos fosfolípidos y usos de los mismos | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
| PE20150773A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilefrina | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| NI202000085A (es) | Moduladores de la expresión de apol1 | |
| CL2023001062A1 (es) | Compuestos fosfolípidos y usos de estos | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| AR026911A1 (es) | Preparado farmaceutica para el tratamiento de afecciones tumorales | |
| BR112022012283A2 (pt) | Combinações | |
| AR128761A1 (es) | Compuesto heterocíclico para inducir la degradación de la proteína kras mutante en g12d | |
| BR112019006633A2 (pt) | combinações farmacêuticas de inibidor de histona desacetilase e inibidor de proteassoma ou fármaco imunomodulador para o tratamento de câncer hematológico |